Petros Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PETROS PHARMACEUTICALS, INC. | ||
| March 31, 2025 | By: | /s/ Fady Boctor |
|---|---|---|
| Name: | Fady Boctor | |
| | Title: | President and Chief Commercial Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | | Date |
|---|---|---|---|
| /s/ Fady Boctor | President and Chief Commercial Officer | March 31, 2025 | |
| Fady Boctor | (Principal Executive Officer) | ||
| /s/ Mitchell Arnold | Vice President of Finance | March 31, 2025 | |
| Mitchell Arnold | (Principal Financial and Accounting Officer) | ||
| /s/ Joshua N. Silverman | Chairman of the Board | March 31, 2025 | |
| Joshua N. Silverman | |||
| /s/ Bruce T. Bernstein | Director | March 31, 2025 | |
| Bruce T. Bernstein | |||
| /s/ Wayne R. Walker | Director | March 31, 2025 | |
| Wayne R. Walker | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.